Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD

Conditions: Crohn ' s Disease Interventions: Drug: Infliximab-Dyyb Sponsors: Asan Medical Center; Seoul National University Hospital; Severance Hospital; Kyung Hee University Hospital; Kyungpook National University Hospital; Samsung Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials